LP-108 + Azacitidine combination
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-11 — A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML: Phase 1 dose-escalation/expansion trial registered to evaluate safety, PK, and preliminary efficacy of LP-108 (BCL-2 inhibitor) combined with azacitidine in AML, MDS, and CMML (trial-early). (novelty: 3)
Open questions
Related
Contributing findings
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
11-sep-2026
novelty 3
per-area 3
introduces